Otsuka Pakistan Limited (PSX:OTSU)

Market Cap	2.77B
Revenue (ttm)	3.69B
Net Income (ttm)	31.27M
Shares Out	12.10M
EPS (ttm)	2.59
PE Ratio	88.61
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	259,232
Average Volume	65,957
Open	218.40
Previous Close	208.48
Day's Range	216.00 - 229.33
52-Week Range	105.05 - 235.98
Beta	0.35
RSI	72.38
Earnings Date	Apr 25, 2025

About Otsuka Pakistan

Otsuka Pakistan Limited manufactures, markets, and distributes intravenous infusions in Pakistan and Afghanistan. The company offers intravenous solutions, including electrolyte and standard solutions, ampoules, OTSUZOL, and ciprofloxacin and OTSUMOL infusion products; medical devices, such as urea breath test systems, plasline solutions, sirolimus eluting coronary stent system, eucaLIMUS, and eucaVI; clinical nutrition products comprising aminoleban oral, aminovel 600, pan-amin G, aminoleban injection, and proten gold; and therapeutic drugs, w...

• Industry: Pharmaceuticals
• Sector: Healthcare
• Founded: 1988
• Employees: 345
• Stock Exchange: Pakistan Stock Exchange
• Ticker Symbol: OTSU

Financial Performance

In 2024, Otsuka Pakistan's revenue was 3.16 billion, an increase of 4.24% compared to the previous year's 3.04 billion. Losses were -4.76 million, -33.91% less than in 2023.